i2o Therapeutics is a technology company.
i2o Therapeutics has raised $4.0M across 1 funding round.
i2o Therapeutics has raised $4.0M in total across 1 funding round.
i2o Therapeutics has raised $4.0M in total across 1 funding round.
i2o Therapeutics's investors include Flagship Ventures, Sanofi Ventures, T1D Fund.
i2o Therapeutics is a Boston-based biotechnology company developing next-generation long-acting biologic therapies for obesity, overweight, type 2 diabetes, and related cardiovascular, renal, and metabolic diseases[1][2][3]. It focuses on a pipeline of once-monthly or quarterly mono- and combination therapies, including GLP-1 receptor agonists (RAs), amylin DACRAs, PYY RAs, and glucagon RAs, designed for optimized pharmacokinetics (PK), improved gastrointestinal tolerability, and simplified dosing without titration[1][3]. These assets target unmet needs in cardio-renal-metabolic conditions by enabling more patients to achieve full therapeutic benefits[1].
The company serves patients with obesity and metabolic disorders, addressing challenges like poor adherence to frequent injections and side effects from existing therapies[1][2]. Early momentum stems from its Harvard-originated innovations in oral and long-acting peptide formulations, positioning it in the booming GLP-1 market[2][4].
i2o Therapeutics emerged from pioneering research at Harvard University, leveraging breakthroughs in biologic and peptide delivery to create safe, effective oral formulations and long-acting therapies[2][4]. Founded as a Boston-area biotech startup, it builds on academic foundations to translate lab discoveries into a robust pipeline, though specific founders and exact founding year details remain undisclosed in available sources[2][4]. Key early traction includes assembling a "rich pipeline" of differentiated assets like long-acting GLP-1s and amylin analogs, amid rising demand for obesity treatments[1][3]. Headquartered in Dedham, Massachusetts, the company has gained visibility through events like the BIO International Convention[1].
i2o stands out in the crowded GLP-1 and metabolic therapy space through these key advantages:
i2o rides the explosive GLP-1 agonist wave, fueled by blockbuster drugs like semaglutide that have redefined obesity as a treatable chronic disease, with the market projected to exceed $100B by 2030. Its timing aligns with surging demand for next-gen therapies amid supply shortages and payer pressures for cost-effective, patient-friendly options[1][3]. Favorable market forces include regulatory tailwinds for metabolic combos (e.g., FDA nods for dual agonists) and Big Pharma partnerships seeking differentiated assets[3]. By advancing long-acting peptides, i2o influences the ecosystem toward infrequent dosing standards, potentially accelerating adoption in primary care and lowering long-term healthcare costs.
i2o is poised for milestone advancements, with pipeline readouts likely driving partnerships or Series A/B funding in 2026 amid GLP-1 expansion into new indications like heart failure[1][3]. Trends like AI-accelerated drug discovery and oral peptide breakthroughs will amplify its edge, though execution risks in clinical trials loom[2][4]. Its influence could grow by licensing assets to majors, solidifying Boston's biotech hub status and delivering on the promise of transformative, accessible metabolic therapies—echoing its high-level mission to optimize patient outcomes in a high-stakes field[1][3].
i2o Therapeutics has raised $4.0M across 1 funding round. Most recently, it raised $4.0M Seed in April 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2020 | $4.0M Seed | Flagship Ventures, Sanofi Ventures, T1D Fund |